At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 1,069 enrolled
Drug / intervention
PF-02341066drug
Likely dose
PF-02341066 250 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 2, Open-label Single Arm Study Of The Efficacy And Safety Of Pf-02341066 In Patients With Advanced Non-small Cell Lung Cancer (Nsclc) Harboring A Translocation Or Inversion Involving The Anaplastic Lymphoma Kinase (Alk) Gene Locus
In Brief
A Phase 2 clinical trial evaluating PF-02341066 for Carcinoma, Non-Small-Cell Lung. Completed, enrolled 1,069 participants across 280 sites in 22 countries.
Detailed Summary
This is a Phase 2 trial that will evaluate the safety and efficacy of PF-02341066 in patients with advanced non-small cell lung cancer with a specific gene profile involving the ALK gene. This trial will also allow patients from a Phase 3 trial who received standard of care chemotherapy (Study A8081007) to receive PF-02341066.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Non-Small-Cell Lung
CountriesAustralia, Brazil, Bulgaria, Canada, China, France, Germany, Greece, Hong Kong, Hungary, Ireland, Italy, Japan, Netherlands, Poland, Russia, South Korea, Spain, Sweden, Taiwan, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJul 2009
Enrollment StartJan 2010
Primary CompletionMar 2015
Study CompletionDec 2015
TodayJul 2026
First PostedJul 3, 2009
Enrollment StartJan 1, 2010
Primary CompletionMar 1, 2015
Study CompletionDec 1, 2015
TodayJul 2, 2026
Enrollment to primary: 5.2 yearsPosted 17.0 years ago
Interventions
PF-02341066drug
PF-02341066, 250 mg BID, will be administered orally on a continuous schedule